Answers are grounded in this paper and cite their sources.
Gains in BCVA in this real-life study were lower than those observed in randomized clinical trials with ranibizumab, mainly due to undertreatment. Safety analysis of ranibizumab did not yield any new safety concerns.
No takes yet. Share an insight, caveat, or question.
Massin et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: